Reuters logo
BRIEF-Sophiris Bio currently evaluating options to further advance clinical development of Topsalysin
August 22, 2016 / 8:31 PM / a year ago

BRIEF-Sophiris Bio currently evaluating options to further advance clinical development of Topsalysin

Aug 22 (Reuters) - Sophiris Bio Inc :

* Currently evaluating options to further advance clinical development of topsalysin - sec filing

* “will require significant additional funding to advance topsalysin in clinical development”

* Could use dilutive funding options like equity financing or “non-dilutive” funding options to fund future clinical development of topsalysin

* Do not plan on pursuing new clinical trials, including a second phase 3 trial in bph, unless we obtain additional financing

* Believe that earliest we could commercialize topsalysin for treatment of localized prostate cancer would be in late 2021 or into 2022 Source text (bit.ly/2bHNTCN) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below